Low-dosage methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease

Pharmacotherapy

Volumn 22, Issue 5, 2002, Pages 613-620

  Vandell, Alexander G ^a,b   DiPiro, Joseph T ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; FOLIC ACID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISONE;

ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CROHN DISEASE; DRUG COST; DRUG EFFICACY; ENTERITIS; HEADACHE; HUMAN; LIVER TOXICITY; LUNG TOXICITY; NAUSEA AND VOMITING; PAIN; PATIENT MONITORING; REMISSION; RHINITIS; STEROID THERAPY; ULCERATIVE COLITIS;

EID: 0036235011     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.8.613.33208     Document Type: Article

References (20)

1. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease
2. Antineoplastic agents
3. Newer treatments for inflammatory bowel disease
4. Medical therapy for inflammatory bowel disease
5. Office management of common anorectal problems
6. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
7. A preliminary study of growth hormone therapy for Crohn's disease
8. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
9. Methotrexate in chronic active Crohn's disease: A double blind, randomized, Israeli multicenter trial
10. Methotrexate in Crohn's disease: Results of a randomized, double-blind, placebo-controlled trial
11. Methotrexate in Crohn's disease: Long-term safety and toxicity
12. Low-dose oral methotrexate in refractory inflammatory bowel disease
13. Methotrexate in refractory Crohn's disease
14. Efficacy of parenteral methotrexate in refractory Crohn's disease
15. Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial
16. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84 Month update
17. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease
18. Immunosuppressors for inflammatory bowel disease: How long is long enough?
19. The absorption of low-dose methotrexate in patients with inflammatory bowel disease